Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

By Argiris Athanassios  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1575-1584

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies

By Sayar H.   Shen Z.   Lee S.   Royce M.   Rabinowitz I.   Lee F.   Smith H.   Eberhardt S.   Maestas A.   Lu H.   Verschraegen C.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 153-158

Springer Publishing Company

Access to resources Recommend Favorite

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

By Faris Jason  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1614-1620

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers

By Goel Sanjay   Desai Kavita   Karri Sirisha   Gollamudi Radharani   Chaudhary Imran   Bulgaru Anca   Kaubisch Andreas   Goldberg Gary   Einstein Mark   Camacho Fernando   Baker Sharyn   Mani Sridhar  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 237-245

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

By Richter Suzanne   Bedard Philippe   Chen Eric   Clarke Blaise   Tran Ben   Hotte Sebastien   Stathis Anastasios   Hirte Hal   Razak Albiruni   Reedijk Michael   Chen Zhuo   Cohen Brenda   Zhang Wen-Jiang   Wang Lisa   Ivy S.   Moore Malcolm   Oza Amit   Siu Lillian   McWhirter Elaine  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 243-249

Springer Publishing Company

Access to resources Recommend Favorite